DSS-treated mice receiving a suboptimal amount (meaning lower, i.e., 3 × 105 cells per mouse when compared with levels that were previously established as optimal) of D3R-deficient Treg cells presented with an improvement of the colitis manifestation in comparison with DSS-treated mice receiving D3R-sufficient GFP+CD4+ Treg cells, or those that were only DSS-treated (without the Treg cell transfer). This evidence concerns the gene CD4 and colitis.